Study	Reason for exclusion
Baloh 2014	This ongoing clinical trial focuses on treatment, not prevention and was excluded for this reason
Gode 2010	This study compared 2 doses of topiramate (50 mg/day or 100 mg/day); there was no placebo or no treatment group
Lepcha 2013	This study used the Neuhauser diagnostic criteria; according to the protocol for this review, we only included studies using the Bárány Society/International Headache Society diagnostic criteria
Liu 2013	This study did not use standard criteria for the diagnosis of vestibular migraine; according to the protocol for this review, we only included studies using the Bárány Society/International Headache Society diagnostic criteria
Lustig 2008	This trial was excluded because it was withdrawn before the enrolment of any patients
Mikulec 2014	This was a cross‐over trial with 2 active comparators (nortriptyline and topiramate) and no placebo or no treatment arm. Patients could switch to the other intervention within the first treatment period if they were intolerant. In addition, it does not meet the diagnostic inclusion criteria; according to the protocol for this review, we only included studies using the Bárány Society/International Headache Society diagnostic criteria
Neuhauser 2003	This study was focused on the treatment, not the prevention, of vestibular migraine
Salviz 2014	This ongoing clinical trial is comparing the efficacy of venlafaxine to propanolol. It was excluded because the comparator is an active intervention, not placebo
Staab 2012	This study did not focus on the effectiveness of preventive treatment of vestibular migraine, but on clarifying the diagnostic criteria for vestibular migraine and chronic subjective dizziness
Wu 2007	This study was not a true clinical trial comparing the effectiveness of an intervention with a control; it was a trial comparing a group before and after an intervention